首页 > 最新文献

Clinica e Investigacion en Arteriosclerosis最新文献

英文 中文
Estrategias de tratamiento de las dislipemias en prevención primaria y secundaria. Registro de la Sociedad Española de Arteriosclerosis 血脂异常在一级和二级预防中的治疗策略。西班牙动脉硬化学会注册
IF 1.6 Q3 Medicine Pub Date : 2022-11-01 DOI: 10.1016/j.arteri.2022.03.007
Victoria Marco-Benedí , Ana M. Bea , Rosa M. Sánchez Hernández , Núria Plana , Pedro Valdivielso , Fernando Civeira

Introduction

Clinical studies show that patients with high cardiovascular risk are still far from reaching the therapeutic objectives, especially of the levels of LDL cholesterol. If the management of these patients in specialized units differs from other scenarios is known.

Patients and methods

61 certified Lipid Units were selected in the Registry of Dyslipemias of the Spanish Arteriosclerosis Society for the collection of study data.

The study included 3958 subjects >18 years of age who met the criteria for hypercholesterolemia (LDL cholesterol ≥160 mg/dL or non-HDL cholesterol ≥190 mg/dL) without familial hypercholesterolemia. A total 1,665 subjects were studied with a mean follow-up time of 4.2 years.

Results and conclusions

A total of 42 subjects had a cardiovascular event since their inclusion in the Registry, which represents 0.6%. There were no differences in the treatment used at follow-up, but 50% of the patients did not reach the therapeutic goals at the visit end of follow-up. An increase in the potency of the lipid-lowering treatment was observed, including PCSK9 inhibitors use in 16.7% of subjects with recurrences.

临床研究表明,心血管高危患者仍远未达到治疗目标,特别是低密度脂蛋白胆固醇水平。如果这些患者在专科病房的管理不同于其他情况是已知的。在西班牙动脉硬化学会的血脂异常登记处选择了61个经认证的脂质单位来收集研究数据。该研究包括3958名18岁符合高胆固醇血症标准(低密度脂蛋白胆固醇≥160 mg/dL或非高密度脂蛋白胆固醇≥190 mg/dL)且无家族性高胆固醇血症的受试者。共有1665名受试者被研究,平均随访时间为4.2年。结果和结论自纳入登记以来,共有42名受试者发生心血管事件,占0.6%。随访时所采用的治疗方法无差异,但有50%的患者在随访结束时未达到治疗目标。观察到降脂治疗的效力增加,包括16.7%的复发患者使用PCSK9抑制剂。
{"title":"Estrategias de tratamiento de las dislipemias en prevención primaria y secundaria. Registro de la Sociedad Española de Arteriosclerosis","authors":"Victoria Marco-Benedí ,&nbsp;Ana M. Bea ,&nbsp;Rosa M. Sánchez Hernández ,&nbsp;Núria Plana ,&nbsp;Pedro Valdivielso ,&nbsp;Fernando Civeira","doi":"10.1016/j.arteri.2022.03.007","DOIUrl":"10.1016/j.arteri.2022.03.007","url":null,"abstract":"<div><h3>Introduction</h3><p>Clinical studies show that patients with high cardiovascular risk are still far from reaching the therapeutic objectives, especially of the levels of LDL cholesterol. If the management of these patients in specialized units differs from other scenarios is known.</p></div><div><h3>Patients and methods</h3><p>61 certified Lipid Units were selected in the Registry of Dyslipemias of the Spanish Arteriosclerosis Society for the collection of study data.</p><p>The study included 3958 subjects &gt;18 years of age who met the criteria for hypercholesterolemia (LDL cholesterol ≥160 mg/dL or non-HDL cholesterol ≥190 mg/dL) without familial hypercholesterolemia. A total 1,665 subjects were studied with a mean follow-up time of 4.2 years.</p></div><div><h3>Results and conclusions</h3><p>A total of 42 subjects had a cardiovascular event since their inclusion in the Registry, which represents 0.6%. There were no differences in the treatment used at follow-up, but 50% of the patients did not reach the therapeutic goals at the visit end of follow-up. An increase in the potency of the lipid-lowering treatment was observed, including PCSK9 inhibitors use in 16.7% of subjects with recurrences.</p></div>","PeriodicalId":45230,"journal":{"name":"Clinica e Investigacion en Arteriosclerosis","volume":null,"pages":null},"PeriodicalIF":1.6,"publicationDate":"2022-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"54195074","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 1
Actualización sobre las nuevas formas de consumo de tabaco 关于新形式烟草消费的最新情况
IF 1.6 Q3 Medicine Pub Date : 2022-11-01 DOI: 10.1016/j.arteri.2022.03.004
Jorge Francisco Gómez Cerezo , José Enrique López Paz , Jacinto Fernández Pardo

Smoking remains the leading cause of morbidity and mortality worldwide. Because of its clear influence on cardiovascular and respiratory diseases, it is an important factor in internal medicine consultations. Although the rate of smoking cessation has been increasing in recent years, there is a percentage of patients who continue to smoke because they are unable or unwilling to quit, despite having tried existing pharmacological and non-pharmacological therapies. For this group of patients there are strategies based on interventions aimed at reducing the negative effects of smoking without the need for complete cessation. In this review it is shown that due to the absence of combustion of organic matter in conventional cigarettes, snus, e-cigarettes and heated tobacco products generate significantly lower levels of toxic substances.

吸烟仍然是全世界发病率和死亡率的主要原因。由于其对心血管和呼吸系统疾病的影响明显,是内科会诊的重要因素。尽管近年来戒烟率一直在上升,但仍有一定比例的患者继续吸烟,因为他们无法或不愿戒烟,尽管已经尝试了现有的药物和非药物治疗。对于这组患者,有一些基于干预措施的策略,旨在减少吸烟的负面影响,而不需要完全戒烟。这篇综述表明,由于传统香烟中没有有机物的燃烧,鼻烟、电子烟和加热烟草产品产生的有毒物质水平明显较低。
{"title":"Actualización sobre las nuevas formas de consumo de tabaco","authors":"Jorge Francisco Gómez Cerezo ,&nbsp;José Enrique López Paz ,&nbsp;Jacinto Fernández Pardo","doi":"10.1016/j.arteri.2022.03.004","DOIUrl":"10.1016/j.arteri.2022.03.004","url":null,"abstract":"<div><p>Smoking remains the leading cause of morbidity and mortality worldwide. Because of its clear influence on cardiovascular and respiratory diseases, it is an important factor in internal medicine consultations. Although the rate of smoking cessation has been increasing in recent years, there is a percentage of patients who continue to smoke because they are unable or unwilling to quit, despite having tried existing pharmacological and non-pharmacological therapies. For this group of patients there are strategies based on interventions aimed at reducing the negative effects of smoking without the need for complete cessation. In this review it is shown that due to the absence of combustion of organic matter in conventional cigarettes, snus, e-cigarettes and heated tobacco products generate significantly lower levels of toxic substances.</p></div>","PeriodicalId":45230,"journal":{"name":"Clinica e Investigacion en Arteriosclerosis","volume":null,"pages":null},"PeriodicalIF":1.6,"publicationDate":"2022-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S0214916822000377/pdfft?md5=02d6adb35580061a733a0d4895094a21&pid=1-s2.0-S0214916822000377-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"54194768","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Efecto de la administración de diferentes formas de vitamina D en la presión arterial y rigidez aórticas, y su implicación en la reducción de la albuminuria en la enfermedad renal crónica 不同形式的维生素D对血压和主动脉僵硬的影响,以及它们在减少慢性肾脏疾病白蛋白尿中的作用
IF 1.6 Q3 Medicine Pub Date : 2022-11-01 DOI: 10.1016/j.arteri.2022.05.002
Almudena Martin-Romero , Jary Perelló-Martínez , Juan Carlos Hidalgo-Santiago , Alfredo Michan-Doña , Juan Bosco López Sáez , Pablo Gómez-Fernández

Background and objectives

Vitamin D(vitD) participates in phospho-calcium metabolism and exerts multiple pleiotropic effects. There is tissue 1-α (OH)ase that converts 25-OH cholecalciferol (25 (OH) D) in calcitriol that exerts autocrine and paracrine effects. 25 (OH)D deficiency could limit these tissue effects of vitD. The administration of nutritional vitD and the activator of the vitD receptor, paricalcitol, may promote beneficial effects on vascular and renal function. The objective of this work was to study in subjects with chronic kidney disease (CKD) the effect that the administration of different forms of vitD has on arterial function and albuminuria, and the possible relationship between the modifications of these variables.

Patients and methods

We studied in 97 patients with CKD stages 3-4 the effect of the administration of cholecalciferol (group 2; n: 35) and paricalcitol (n: 31; group 3) on parameters derived from brachial blood pressure, aortic blood pressure and on aortic stiffness studied using carotid-femoral pulse velocity (Vpc-f), and on albuminuria. A group of patients with stages 3-4 CKD who did not receive vitD therapy served as a control group (n: 31; group 1). All parameters were studied at baseline and after the follow-up period which was 7 ± 2 months.

Results

In the baseline phase, no differences were observed between the groups in brachial systolic blood pressure (bSBP), central systolic blood pressure (SBP), brachial pulse pressure (bPP), and central pulse pressure (pCP) or in aortic stiffness that was increased in all groups with a baseline Vpc-f value of 10.5 (9.2-12.1) m/sec. The baseline albuminuria value in the grouped patients was 229 (43-876) mg / g (median (interquartile range)), with no differences between the groups.

Serum calcium and phosphorus increased significantly in those treated with cholecal-ciferol (native vitD) and paricalcitol (active vitD). Parathormone (PTH) values decreased in those treated with paricalcitol.bPP and cPP decreased in all groups treated with native and active vitD. No significant changes in bPP and cPP were observed in the control group.

Vpc-f did not change significantly in any of the groups, although the variation was quantitatively greater in group 3 (11.2±2 vs. 10.7±1.6 (P=.06)). No differences were observed in the changes in Vpc-f between the groups when adjusted to the baseline values of estimated glomerular filtration rate (eGFR), albuminuria, PTH, vitD, brachial and central blood pressure parameters, and their changes with treatment.Those who received treatment with native and active vitD presented a significant decrease in albuminuria of 17% (group 2) and 21% (group 3) compared to a 16% increase in the untreated group (group 1) (P=.01). A decrease in albuminuria ≥30% was observed more frequently in the groups treated with some form o

背景与目的维生素D(vitD)参与磷钙代谢,发挥多种多效作用。骨化三醇中有组织1-α (OH)酶转化25-OH胆骨化醇(25 (OH) D),发挥自分泌和旁分泌作用。缺乏25 (OH)D可以限制维生素D的这些组织作用。营养维生素d和维生素d受体的激活剂,特别是糖醇,可以促进血管和肾脏功能的有益作用。本研究的目的是研究慢性肾脏疾病(CKD)患者服用不同形式的维生素d对动脉功能和蛋白尿的影响,以及这些变量的改变之间可能的关系。患者和方法我们研究了97例CKD 3-4期患者给予胆钙化醇的效果(2组;N: 35)和paricalcitol (N: 31;第3组)肱血压、主动脉血压、颈-股动脉脉速(vc -f)研究的主动脉硬度参数和蛋白尿。一组未接受vitD治疗的3-4期CKD患者作为对照组(n: 31;1组)。在基线及随访(7±2个月)后进行各项指标的研究。结果基线期各组间肱收缩压(bSBP)、中心收缩压(SBP)、肱脉压(bPP)、中心脉压(pCP)均无差异,各组间主动脉硬度均升高,基线Vpc-f值为10.5 (9.2-12.1)m/sec。分组患者的基线蛋白尿值为229 (43-876)mg / g(中位数(四分位数范围)),组间无差异。血清钙和磷在使用胆-枸橼醇(天然维生素d)和部分枸橼醇(活性维生素d)治疗组显著升高。paricalcitol治疗组甲状旁腺激素(PTH)值降低。所有天然和活性维生素d治疗组的bPP和cPP均下降。对照组bPP、cPP无明显变化。Vpc-f在任何组中都没有显著变化,尽管在数量上变化在第3组更大(11.2±2比10.7±1.6 (P=.06))。当调整到肾小球滤过率(eGFR)、蛋白尿、甲状旁腺素(PTH)、vitD、肱和中枢血压参数的基线值时,两组间Vpc-f的变化及其随治疗的变化无差异。与未治疗组(1组)增加16%相比,接受天然和活性维生素d治疗的患者蛋白尿显著减少17%(2组)和21%(3组)(P= 0.01)。在接受某种形式维生素d治疗的组中,蛋白尿下降≥30%的情况更为常见(组2:23%;第3组:45%)高于对照组(13%)(P=.03)。当引入磷钙代谢的生化参数基线值、动脉功能(PPb、PPc、Vpc-f)或其修改值作为协变量时,任何形式的vitD治疗组观察到的蛋白尿减少都没有变化。Vpc-f变化与蛋白尿无显著相关性。在逻辑回归中,动脉功能参数的改变也不能解释蛋白尿减少≥30%的原因。结论在3-4期CKD患者中,接受RAS受体阻滞剂治疗并伴有残余蛋白尿,给予或特定的糖醇可降低肱动脉脉压和主动脉脉压以及蛋白尿。蛋白尿的减少似乎不是由中央血流动力学或主动脉僵硬的改变介导的,至少不是决定性的。
{"title":"Efecto de la administración de diferentes formas de vitamina D en la presión arterial y rigidez aórticas, y su implicación en la reducción de la albuminuria en la enfermedad renal crónica","authors":"Almudena Martin-Romero ,&nbsp;Jary Perelló-Martínez ,&nbsp;Juan Carlos Hidalgo-Santiago ,&nbsp;Alfredo Michan-Doña ,&nbsp;Juan Bosco López Sáez ,&nbsp;Pablo Gómez-Fernández","doi":"10.1016/j.arteri.2022.05.002","DOIUrl":"10.1016/j.arteri.2022.05.002","url":null,"abstract":"<div><h3>Background and objectives</h3><p>Vitamin D(vitD) participates in phospho-calcium metabolism and exerts multiple pleiotropic effects. There is tissue 1-α (OH)ase that converts 25-OH cholecalciferol (25 (OH) D) in calcitriol that exerts autocrine and paracrine effects. 25 (OH)D deficiency could limit these tissue effects of vitD. The administration of nutritional vitD and the activator of the vitD receptor, paricalcitol, may promote beneficial effects on vascular and renal function. The objective of this work was to study in subjects with chronic kidney disease (CKD) the effect that the administration of different forms of vitD has on arterial function and albuminuria, and the possible relationship between the modifications of these variables.</p></div><div><h3>Patients and methods</h3><p>We studied in 97 patients with CKD stages 3-4 the effect of the administration of cholecalciferol (group 2; n: 35) and paricalcitol (n: 31; group 3) on parameters derived from brachial blood pressure, aortic blood pressure and on aortic stiffness studied using carotid-femoral pulse velocity (Vp<sub>c-f</sub>), and on albuminuria. A group of patients with stages 3-4 CKD who did not receive vitD therapy served as a control group (n: 31; group 1). All parameters were studied at baseline and after the follow-up period which was 7 ± 2 months.</p></div><div><h3>Results</h3><p>In the baseline phase, no differences were observed between the groups in brachial systolic blood pressure (bSBP), central systolic blood pressure (SBP), brachial pulse pressure (bPP), and central pulse pressure (pCP) or in aortic stiffness that was increased in all groups with a baseline Vp<sub>c-f</sub> value of 10.5 (9.2-12.1) m/sec. The baseline albuminuria value in the grouped patients was 229 (43-876) mg / g (median (interquartile range)), with no differences between the groups.</p><p>Serum calcium and phosphorus increased significantly in those treated with cholecal-ciferol (native vitD) and paricalcitol (active vitD). Parathormone (PTH) values decreased in those treated with paricalcitol.bPP and cPP decreased in all groups treated with native and active vitD. No significant changes in bPP and cPP were observed in the control group.</p><p>Vp<sub>c-f</sub> did not change significantly in any of the groups, although the variation was quantitatively greater in group 3 (11.2±2 vs. 10.7±1.6 <em>(P=</em>.06)). No differences were observed in the changes in Vp<sub>c-f</sub> between the groups when adjusted to the baseline values of estimated glomerular filtration rate (eGFR), albuminuria, PTH, vitD, brachial and central blood pressure parameters, and their changes with treatment.Those who received treatment with native and active vitD presented a significant decrease in albuminuria of 17% (group 2) and 21% (group 3) compared to a 16% increase in the untreated group (group 1) <em>(P=</em>.01). A decrease in albuminuria ≥30% was observed more frequently in the groups treated with some form o","PeriodicalId":45230,"journal":{"name":"Clinica e Investigacion en Arteriosclerosis","volume":null,"pages":null},"PeriodicalIF":1.6,"publicationDate":"2022-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"40493716","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 1
Tasas de prevalencia de sobrepeso y obesidad y sus asociaciones con factores cardiometabólicos y renales. Estudio SIMETAP-OB 超重和肥胖的患病率及其与心脏代谢和肾脏因素的关系。研究SIMETAP-OB
IF 1.6 Q3 Medicine Pub Date : 2022-11-01 DOI: 10.1016/j.arteri.2022.03.006
Antonio Ruiz-García , Ezequiel Arranz-Martínez , Luis Enrique Morales-Cobos , Juan Carlos García-Álvarez , Nerea Iturmendi-Martínez , Montserrat Rivera-Teijido , en representación del Grupo de Investigación del Estudio SIMETAP

Introduction

Excess weight is a major health problem. Aims of this study were to determine the prevalence rates of overweight and obesity, and to compare their associations with cardiometabolic and renal risk factors between obese and non-obese populations, and between overweight and non-overweight populations.

Methods

Cross-sectional observational study conducted in Primary Care. Population-based random sample: 6,588 study subjects between 18 and 102 years of age (response rate: 66%). Crude and sex- and age-adjusted prevalence rates of overweight and obesity were calculated, and their associations with cardiometabolic and renal variables were assessed by bivariate and multivariate analysis.

Results

The age- and sex-adjusted prevalence rates of overweight and obesity were 36.0% (42.1% in men; 33.1% in women) and 25.0% (26.2% in men; 24.5% in women), respectively. These prevalences increased with age, and were higher in men than in women. Fifty-two percent (95%CI: 50.0-53.9) of the overweight population and 62.3% (95%CI: 60.1-64.5) of the obese population had a high or very high cardiovascular risk. Abdominal obesity, physical inactivity, prediabetes, hypertension, hypertriglyceridemia, and low HDL-C were independently associated with both entities. Furthermore, diabetes was independently associated with overweight and hypercholesterolemia with obesity.

Conclusions

The prevalence of overweight and obesity was 61.0% (68.4% in men and 59.0% in women). More than half of the overweight population and nearly two-thirds of the obese population had a high cardiovascular risk. Hyperglycemia, physical inactivity, hypertension, hypercholesterolemia, low HDL-C, and hypertriglyceridemia were independently associated with overweight and obesity.

超重是一个主要的健康问题。本研究的目的是确定超重和肥胖的患病率,并比较肥胖和非肥胖人群、超重和非超重人群与心脏代谢和肾脏危险因素的关系。方法在初级保健部门进行横断面观察研究。基于人群的随机样本:6588名年龄在18至102岁之间的研究对象(应答率:66%)。计算超重和肥胖的粗患病率以及性别和年龄调整后的患病率,并通过双变量和多变量分析评估其与心脏代谢和肾脏变量的关联。结果经年龄和性别调整后的超重和肥胖患病率为36.0%(男性42.1%;女性33.1%)和25.0%(男性26.2%;女性为24.5%)。这些患病率随着年龄的增长而增加,男性高于女性。52% (95%CI: 50.0-53.9)的超重人群和62.3% (95%CI: 60.1-64.5)的肥胖人群有较高或非常高的心血管风险。腹部肥胖、缺乏运动、前驱糖尿病、高血压、高甘油三酯血症和低HDL-C与这两种实体独立相关。此外,糖尿病与超重和高胆固醇血症与肥胖独立相关。结论超重和肥胖患病率为61.0%,其中男性为68.4%,女性为59.0%。超过一半的超重人群和近三分之二的肥胖人群患心血管疾病的风险很高。高血糖、缺乏运动、高血压、高胆固醇血症、低HDL-C和高甘油三酯血症与超重和肥胖独立相关。
{"title":"Tasas de prevalencia de sobrepeso y obesidad y sus asociaciones con factores cardiometabólicos y renales. Estudio SIMETAP-OB","authors":"Antonio Ruiz-García ,&nbsp;Ezequiel Arranz-Martínez ,&nbsp;Luis Enrique Morales-Cobos ,&nbsp;Juan Carlos García-Álvarez ,&nbsp;Nerea Iturmendi-Martínez ,&nbsp;Montserrat Rivera-Teijido ,&nbsp;en representación del Grupo de Investigación del Estudio SIMETAP","doi":"10.1016/j.arteri.2022.03.006","DOIUrl":"10.1016/j.arteri.2022.03.006","url":null,"abstract":"<div><h3>Introduction</h3><p>Excess weight is a major health problem. Aims of this study were to determine the prevalence rates of overweight and obesity, and to compare their associations with cardiometabolic and renal risk factors between obese and non-obese populations, and between overweight and non-overweight populations.</p></div><div><h3>Methods</h3><p>Cross-sectional observational study conducted in Primary Care. Population-based random sample: 6,588 study subjects between 18 and 102 years of age (response rate: 66%). Crude and sex- and age-adjusted prevalence rates of overweight and obesity were calculated, and their associations with cardiometabolic and renal variables were assessed by bivariate and multivariate analysis.</p></div><div><h3>Results</h3><p>The age- and sex-adjusted prevalence rates of overweight and obesity were 36.0% (42.1% in men; 33.1% in women) and 25.0% (26.2% in men; 24.5% in women), respectively. These prevalences increased with age, and were higher in men than in women. Fifty-two percent (95%<span>C</span>I: 50.0-53.9) of the overweight population and 62.3% (95%CI: 60.1-64.5) of the obese population had a high or very high cardiovascular risk. Abdominal obesity, physical inactivity, prediabetes, hypertension, hypertriglyceridemia, and low HDL-C were independently associated with both entities. Furthermore, diabetes was independently associated with overweight and hypercholesterolemia with obesity.</p></div><div><h3>Conclusions</h3><p>The prevalence of overweight and obesity was 61.0% (68.4% in men and 59.0% in women). More than half of the overweight population and nearly two-thirds of the obese population had a high cardiovascular risk. Hyperglycemia, physical inactivity, hypertension, hypercholesterolemia, low HDL-C, and hypertriglyceridemia were independently associated with overweight and obesity.</p></div>","PeriodicalId":45230,"journal":{"name":"Clinica e Investigacion en Arteriosclerosis","volume":null,"pages":null},"PeriodicalIF":1.6,"publicationDate":"2022-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"54194802","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 1
¿Por qué los osos pardos están protegidos contra la aterosclerosis a pesar de que sus niveles de colesterol plasmático doblan al de los humanos? 为什么棕熊的血浆胆固醇水平是人类的两倍,却能预防动脉粥样硬化?
IF 1.6 Q3 Medicine Pub Date : 2022-11-01 DOI: 10.1016/j.arteri.2022.09.001
Eva Hurt-Camejo , Matteo Pedrelli

Plasma cholesterol and triglyceride levels are twice as high in hibernating brown bears (Ursus arctos) than in healthy humans. Yet, bears display no sign of atherosclerosis development. To explore this apparent paradox, we analyzed lipoproteins from same ten individual bears plasma collected during winter (hibernation; February) and summer (active; June) in the same year. Plasma from fourteen healthy humans were analyzed as comparator. We used standard methods for lipoprotein isolation, composition and functional investigation. The results shows that in brown bears the absence of atherosclerosis despite elevated cholesterol is likely associated with two main athero-protective properties of circulating lipoproteins. First, a significant ten times lower affinity of low-density-lipoprotein (LDL) particles for arterial proteoglycans and secondly, an elevated plasma cholesterol efflux capacity. What does the brown bear data tell us? That elevated total cholesterol and ApoB-containing lipoproteins not always associates with atherosclerosis disease. We need to look also at the lipoprotein biochemical features and functionality as they are relevant for arterial pathophysiology. What is the translatability into human of these results? We humans need to control our total and LDL-cholesterol levels. We are not brown bears!

冬眠中的棕熊的血浆胆固醇和甘油三酯水平是健康人的两倍。然而,熊没有表现出动脉粥样硬化发展的迹象。为了探究这一明显的悖论,我们分析了在冬季(冬眠;2月)和夏季(活跃;同年六月)。分析了14名健康人的血浆作为比较物。采用标准方法对脂蛋白进行分离、组成和功能研究。结果表明,在棕熊中,尽管胆固醇升高,但没有动脉粥样硬化,这可能与循环脂蛋白的两个主要的动脉粥样硬化保护特性有关。首先,低密度脂蛋白(LDL)颗粒对动脉蛋白聚糖的亲和力显著降低了10倍;其次,血浆胆固醇外排能力升高。棕熊的数据告诉我们什么?总胆固醇和载脂蛋白含量升高并不总是与动脉粥样硬化疾病相关。我们还需要研究脂蛋白的生化特征和功能,因为它们与动脉病理生理有关。这些结果的可翻译性是什么?我们人类需要控制总胆固醇和低密度脂蛋白胆固醇水平。我们不是棕熊!
{"title":"¿Por qué los osos pardos están protegidos contra la aterosclerosis a pesar de que sus niveles de colesterol plasmático doblan al de los humanos?","authors":"Eva Hurt-Camejo ,&nbsp;Matteo Pedrelli","doi":"10.1016/j.arteri.2022.09.001","DOIUrl":"10.1016/j.arteri.2022.09.001","url":null,"abstract":"<div><p>Plasma cholesterol and triglyceride levels are twice as high in hibernating brown bears (<em>Ursus arctos</em>) than in healthy humans<em>.</em> Yet, bears display no sign of atherosclerosis development. To explore this apparent paradox, we analyzed lipoproteins from same ten individual bears plasma collected during winter (hibernation; February) and summer (active; June) in the same year. Plasma from fourteen healthy humans were analyzed as comparator. We used standard methods for lipoprotein isolation, composition and functional investigation. The results shows that in brown bears the absence of atherosclerosis despite elevated cholesterol is likely associated with two main athero-protective properties of circulating lipoproteins. First, a significant ten times lower affinity of low-density-lipoprotein (LDL) particles for arterial proteoglycans and secondly, an elevated plasma cholesterol efflux capacity. What does the brown bear data tell us? That elevated total cholesterol and ApoB-containing lipoproteins not always associates with atherosclerosis disease. We need to look also at the lipoprotein biochemical features and functionality as they are relevant for arterial pathophysiology. What is the translatability into human of these results? We humans need to control our total and LDL-cholesterol levels. We are not brown bears!</p></div>","PeriodicalId":45230,"journal":{"name":"Clinica e Investigacion en Arteriosclerosis","volume":null,"pages":null},"PeriodicalIF":1.6,"publicationDate":"2022-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S0214916822001140/pdfft?md5=89c6bc1b107e8d38ba4434c83c96cb16&pid=1-s2.0-S0214916822001140-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"40669427","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Protocolo del observatorio de las dislipemias: Tratamiento de la hipercolesterolemia en España, contexto e identificación de medidas de mejora en práctica clínica habitual 血脂异常观察方案:西班牙高胆固醇血症的治疗,常规临床实践中的背景和改进措施的确定
IF 1.6 Q3 Medicine Pub Date : 2022-09-01 DOI: 10.1016/j.arteri.2022.02.001
Juan Cosín-Sales , Raquel Campuzano Ruiz , José Luis Díaz Díaz , Carlos Escobar Cervantes , María Rosa Fernández Olmo , Juan José Gómez-Doblas , José María Mostaza , Juan Pedro-Botet , Núria Plana Gil , Pedro Valdivielso

Introduction and objectives

The treatment of dyslipidemia exhibits wide variability in clinical practice and important limitations that make lipid-lowering goals more difficult to attain. Getting to know the management of these patients in clinical practice is key to understand the existing barriers and to define actions that contribute to achieving the therapeutic goals from the most recent Clinical Practice Guidelines.

Methods

Observatory where the information gathered is based on routine clinical practice and the experience from the healthcare professionals involved in the treatment of dyslipidemia in Spain. The information is collected by health area through: (i) face-to-face meeting with three different medical specialties and (ii) quantitative information related to hypercholesterolemia patients’ management (ad-hoc questionnaire). Information includes patients’ profiles, assistance burden, guidelines and protocols used, goal attainment, limitations and opportunities in clinical practice.

Results

145 health areas are planned to be included, with the participation of up to 435 healthcare professionals from the 17 Autonomous Regions of Spain. Information collection will result in aggregated data from over four thousand patients.

Conclusions

This observatory aims to understand how hypercholesterolemia is being treated in routine clinical practice in Spain. Even though the preliminary results show important improvement areas in the treatment of dyslipidemias, mechanisms to drive a change towards health outcomes optimization are also identified.

简介和目的血脂异常的治疗在临床实践中表现出广泛的可变性和重要的局限性,使得降脂目标更难实现。了解这些患者在临床实践中的管理是了解现有障碍的关键,并根据最新的临床实践指南确定有助于实现治疗目标的行动。方法观察站收集的信息是基于常规临床实践和西班牙参与治疗血脂异常的医疗保健专业人员的经验。这些信息是由卫生部门通过以下方式收集的:(i)与三个不同的医学专家面对面会面;(ii)与高胆固醇血症患者管理相关的定量信息(特设问卷)。信息包括患者概况、援助负担、使用的指南和方案、目标实现、临床实践中的限制和机会。结果计划纳入145个保健领域,来自西班牙17个自治区的435名保健专业人员将参与其中。信息收集将产生来自4000多名患者的汇总数据。结论:本观察站旨在了解高胆固醇血症在西班牙的常规临床实践中的治疗情况。尽管初步结果显示了血脂异常治疗的重要改进领域,但也确定了推动健康结果优化变化的机制。
{"title":"Protocolo del observatorio de las dislipemias: Tratamiento de la hipercolesterolemia en España, contexto e identificación de medidas de mejora en práctica clínica habitual","authors":"Juan Cosín-Sales ,&nbsp;Raquel Campuzano Ruiz ,&nbsp;José Luis Díaz Díaz ,&nbsp;Carlos Escobar Cervantes ,&nbsp;María Rosa Fernández Olmo ,&nbsp;Juan José Gómez-Doblas ,&nbsp;José María Mostaza ,&nbsp;Juan Pedro-Botet ,&nbsp;Núria Plana Gil ,&nbsp;Pedro Valdivielso","doi":"10.1016/j.arteri.2022.02.001","DOIUrl":"10.1016/j.arteri.2022.02.001","url":null,"abstract":"<div><h3>Introduction and objectives</h3><p>The treatment of dyslipidemia exhibits wide variability in clinical practice and important limitations that make lipid-lowering goals more difficult to attain. Getting to know the management of these patients in clinical practice is key to understand the existing barriers and to define actions that contribute to achieving the therapeutic goals from the most recent Clinical Practice Guidelines.</p></div><div><h3>Methods</h3><p>Observatory where the information gathered is based on routine clinical practice and the experience from the healthcare professionals involved in the treatment of dyslipidemia in Spain. The information is collected by health area through: (i) face-to-face meeting with three different medical specialties and (ii) quantitative information related to hypercholesterolemia patients’ management (ad-hoc questionnaire). Information includes patients’ profiles, assistance burden, guidelines and protocols used, goal attainment, limitations and opportunities in clinical practice.</p></div><div><h3>Results</h3><p>145 health areas are planned to be included, with the participation of up to 435 healthcare professionals from the 17 Autonomous Regions of Spain. Information collection will result in aggregated data from over four thousand patients.</p></div><div><h3>Conclusions</h3><p>This observatory aims to understand how hypercholesterolemia is being treated in routine clinical practice in Spain. Even though the preliminary results show important improvement areas in the treatment of dyslipidemias, mechanisms to drive a change towards health outcomes optimization are also identified.</p></div>","PeriodicalId":45230,"journal":{"name":"Clinica e Investigacion en Arteriosclerosis","volume":null,"pages":null},"PeriodicalIF":1.6,"publicationDate":"2022-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"54194686","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 1
Impacto de la pandemia por COVID-19 en el control lipídico de pacientes que inician inhibidores de la PCSK9 COVID-19大流行对启动PCSK9抑制剂患者脂质控制的影响
IF 1.6 Q3 Medicine Pub Date : 2022-09-01 DOI: 10.1016/j.arteri.2022.01.003
Jose Seijas-Amigo , Mónica Gayoso-Rey , María José Mauriz-Montero , Pedro Suarez-Artime , Antonia Casas-Martinez , María Dominguez-Guerra , Lara Gonzalez-Freire , Ana Estany-Gestal , Alberto Codero-Fort , Moisés Rodriguez-Mañero , Jose Ramón Gonzalez-Juanatey , e investigadores MEMOGAL

Objectives

MEMOGAL study (NCT04319081) is aimed at evaluating changes in cognitive function in patients treated with PCSK9 inhibitors (PCSK9i). This is the first analysis: (1) discussion about the role of the Hospital Pharmacists during the pandemic, and also the assessment of the impact of COVID-19 in the lipid control; (2) descriptive analysis; (3) effectiveness in LDL cholesterol (LDL-c) reduction of alirocumab and evolocumab; (4) communicate PCSK9i safety.

Material and methods

It is a prospective Real-World Evidence analysis of patients that take PCSK9i for the first time in the usual clinical practice, and they are included after the first dispensation in the public pharmacy consultations of 12 Hospitals in Galicia from May 2020 to April 2021. Baseline values of LDL-c are the previous values before taking PCSK9 and the follow-up values are in 6 months time.

Results

89 patients were included. 86.5% with cardiovascular disease and 53.9% with statin intolerances. 78.8% of the patients were treated with high intensity statins. Statins most used were rosuvastatin (34.1%) and atorvastatin (20.5%). Baseline value of LDL-c was 148 mg/dL and the follow-up value was 71 mg/dL. The baseline value of patients treated with alirocumab (N = 43) was 144 mg/dL and 73 mg/dL in the follow-up. With evolocumab (N = 46) was 151 mg/dL in basaline and 69 mg/dL in follow-up. The LDLc- reduction was 51.21% with evolocumab and 51.05% with alirocumab. 43.1% of the patients showed values >70 mg/dL in six month time; 19.4% between 69 mg/dl and 55 mg/dL and 37.5% <55 mg/dL. 58.3% of the patients achieved a reduction >50% of LDL-c. The adverse events were: injection point reaction (N = 2), myalgias (N = 1), flu-like symptoms (N = 1) and neurocognitive worsening (N = 1).

Conclusions

(1) Despite the number of prescriptions was reduced because of the pandemic, the lipid control was not affected. (2) Half of the patients treated with PSCK9i is due to statins intolerance and the 86% is for secondary prevention. (2) The reduction results were similar to pivotal clinical trials. Despite this, 39% of the total of the patients and 60% of patients with dual teraphy did not reach the goal of ESC/EAS guidelines (< 55 mg/dL and/or reduction > 50%). There were not significant differences between evolocumab and alirocumab: 51.21% vs 51.05% (P = .972). (3) There were not any adverse events of special interest. The possible neurocognitive worsening will be studied as the primary endpoint once the MEMOGAL study has been completed.

memogal研究(NCT04319081)旨在评估接受PCSK9抑制剂(PCSK9i)治疗的患者认知功能的变化。这是第一次分析:(1)讨论了医院药师在大流行期间的作用,并评估了COVID-19对血脂控制的影响;(2)描述性分析;(3) alirocumab和evolocumab降低LDL-c的有效性;(4)沟通PCSK9i安全。材料和方法本研究对在常规临床实践中首次服用PCSK9i的患者进行了前瞻性真实世界证据分析,这些患者在加利西亚12家医院的公共药房咨询中首次配药后被纳入。LDL-c基线值为服用PCSK9前的基线值,随访6个月后的基线值。结果共纳入89例患者。86.5%患有心血管疾病,53.9%患有他汀类药物不耐受。78.8%的患者接受高强度他汀类药物治疗。他汀类药物使用率最高的是瑞舒伐他汀(34.1%)和阿托伐他汀(20.5%)。LDL-c基线值为148 mg/dL,随访值为71 mg/dL。接受alirocumab治疗的患者(N = 43)的基线值在随访中分别为144mg /dL和73mg /dL。evolocumab组(N = 46)基线值为151 mg/dL,随访值为69 mg/dL。evolocumab组ldl -降低51.21%,alirocumab组降低51.05%。43.1%的患者6个月后血压值为70 mg/dL;19.4%介于69和55毫克/分升之间,37.5%介于55毫克/分升之间。58.3%的患者LDL-c降低了50%。不良事件为:注射点反应(N = 2)、肌痛(N = 1)、流感样症状(N = 1)和神经认知恶化(N = 1)。结论(1)大流行虽然减少了处方数量,但对血脂控制没有影响。(2)半数PSCK9i患者是由于他汀类药物不耐受,86%为二级预防。(2)还原结果与关键性临床试验相似。尽管如此,39%的患者和60%的双重治疗患者没有达到ESC/EAS指南的目标(<55毫克/分升和/或降低;50%)。evolocumab和alirocumab之间无显著差异:51.21% vs 51.05% (P = 0.972)。(3)未发生任何值得特别关注的不良事件。一旦MEMOGAL研究完成,可能的神经认知恶化将作为主要终点进行研究。
{"title":"Impacto de la pandemia por COVID-19 en el control lipídico de pacientes que inician inhibidores de la PCSK9","authors":"Jose Seijas-Amigo ,&nbsp;Mónica Gayoso-Rey ,&nbsp;María José Mauriz-Montero ,&nbsp;Pedro Suarez-Artime ,&nbsp;Antonia Casas-Martinez ,&nbsp;María Dominguez-Guerra ,&nbsp;Lara Gonzalez-Freire ,&nbsp;Ana Estany-Gestal ,&nbsp;Alberto Codero-Fort ,&nbsp;Moisés Rodriguez-Mañero ,&nbsp;Jose Ramón Gonzalez-Juanatey ,&nbsp;e investigadores MEMOGAL","doi":"10.1016/j.arteri.2022.01.003","DOIUrl":"10.1016/j.arteri.2022.01.003","url":null,"abstract":"<div><h3>Objectives</h3><p>MEMOGAL study (NCT04319081) is aimed at evaluating changes in cognitive function in patients treated with PCSK9 inhibitors (PCSK9i). This is the first analysis: (1) discussion about the role of the Hospital Pharmacists during the pandemic, and also the assessment of the impact of COVID-19 in the lipid control; (2) descriptive analysis; (3) effectiveness in LDL cholesterol (LDL-c) reduction of alirocumab and evolocumab; (4) communicate PCSK9i safety.</p></div><div><h3>Material and methods</h3><p>It is a prospective Real-World Evidence analysis of patients that take PCSK9i for the first time in the usual clinical practice, and they are included after the first dispensation in the public pharmacy consultations of 12 Hospitals in Galicia from May 2020 to April 2021. Baseline values of LDL-c are the previous values before taking PCSK9 and the follow-up values are in 6 months time.</p></div><div><h3>Results</h3><p>89 patients were included. 86.5% with cardiovascular disease and 53.9% with statin intolerances. 78.8% of the patients were treated with high intensity statins. Statins most used were rosuvastatin (34.1%) and atorvastatin (20.5%). Baseline value of LDL-c was 148<!--> <!-->mg/dL and the follow-up value was 71<!--> <!-->mg/dL. The baseline value of patients treated with alirocumab (<em>N</em> <!-->=<!--> <!-->43) was 144<!--> <!-->mg/dL and 73<!--> <!-->mg/dL in the follow-up. With evolocumab (<em>N</em> <!-->=<!--> <!-->46) was 151<!--> <!-->mg/dL in basaline and 69<!--> <!-->mg/dL in follow-up. The LDLc- reduction was 51.21% with evolocumab and 51.05% with alirocumab. 43.1% of the patients showed values &gt;70<!--> <!-->mg/dL in six month time; 19.4% between 69<!--> <!-->mg/dl and 55<!--> <!-->mg/dL and 37.5% &lt;55<!--> <!-->mg/dL. 58.3% of the patients achieved a reduction &gt;50% of LDL-c. The adverse events were: injection point reaction (<em>N</em> <!-->=<!--> <!-->2), myalgias (<em>N</em> <!-->=<!--> <!-->1), flu-like symptoms (<em>N</em> <!-->=<!--> <!-->1) and neurocognitive worsening (<em>N</em> <!-->=<!--> <!-->1).</p></div><div><h3>Conclusions</h3><p>(1) Despite the number of prescriptions was reduced because of the pandemic, the lipid control was not affected. (2) Half of the patients treated with PSCK9i is due to statins intolerance and the 86% is for secondary prevention. (2) The reduction results were similar to pivotal clinical trials. Despite this, 39% of the total of the patients and 60% of patients with dual teraphy did not reach the goal of ESC/EAS guidelines (&lt;<!--> <!-->55<!--> <!-->mg/dL and/or reduction<!--> <!-->&gt;<!--> <!-->50%). There were not significant differences between evolocumab and alirocumab: 51.21% vs 51.05% (<em>P</em> <!-->=<!--> <!-->.972). (3) There were not any adverse events of special interest. The possible neurocognitive worsening will be studied as the primary endpoint once the MEMOGAL study has been completed.</p></div>","PeriodicalId":45230,"journal":{"name":"Clinica e Investigacion en Arteriosclerosis","volume":null,"pages":null},"PeriodicalIF":1.6,"publicationDate":"2022-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8810305/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10325262","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 1
LDL como objetivo terapéutico 低密度脂蛋白作为治疗靶点
IF 1.6 Q3 Medicine Pub Date : 2022-09-01 DOI: 10.1016/j.arteri.2019.10.008
Ángel Díaz Rodríguez , Teresa Mantilla Morató

The incidence of atherosclerotic cardiovsacular disease (ASCVC) has increased in the developed countries. Dyslipidemia is a primary major risk factor for ASCVD and LDL lowering is one of the main objectives. Although treatment goals for dyslipidemias should be personalized in every patient, statins are cost-effective in primary and secondary prevention of ASCVD. New treatments with higher power and greater decreases in LDL, PSCK9 inhibitors, have made a new breakthrough in ASCVD treatment. The 2019 Guidelines for de Management of Dyslipidaemias: Lipid Modification to reduce Cardiovascular Risk (European Society of Cardiology/European Atherosclerosis Society) with the level of evidence and the strength of the recommendations can facilitate the best decisions and benefits to our patients in clinical practice.

在发达国家,动脉粥样硬化性心血管疾病(ASCVC)的发病率有所上升。血脂异常是ASCVD的主要危险因素,降低LDL是主要目标之一。尽管血脂异常的治疗目标应因人而异,但他汀类药物在ASCVD的一级和二级预防中具有成本效益。新的治疗方法具有更高的功效和更大的降低LDL, PSCK9抑制剂,在ASCVD治疗中取得了新的突破。2019年《血脂异常管理指南:脂质改变以降低心血管风险》(欧洲心脏病学会/欧洲动脉粥样硬化学会),其证据水平和建议的强度有助于在临床实践中为患者做出最佳决策和获益。
{"title":"LDL como objetivo terapéutico","authors":"Ángel Díaz Rodríguez ,&nbsp;Teresa Mantilla Morató","doi":"10.1016/j.arteri.2019.10.008","DOIUrl":"10.1016/j.arteri.2019.10.008","url":null,"abstract":"<div><p>The incidence of atherosclerotic cardiovsacular disease (ASCVC) has increased in the developed countries. Dyslipidemia is a primary major risk factor for ASCVD and LDL lowering is one of the main objectives. Although treatment goals for dyslipidemias should be personalized in every patient, statins are cost-effective in primary and secondary prevention of ASCVD. New treatments with higher power and greater decreases in LDL, PSCK9 inhibitors, have made a new breakthrough in ASCVD treatment. The 2019 Guidelines for de Management of Dyslipidaemias: Lipid Modification to reduce Cardiovascular Risk (European Society of Cardiology/European Atherosclerosis Society) with the level of evidence and the strength of the recommendations can facilitate the best decisions and benefits to our patients in clinical practice.</p></div>","PeriodicalId":45230,"journal":{"name":"Clinica e Investigacion en Arteriosclerosis","volume":null,"pages":null},"PeriodicalIF":1.6,"publicationDate":"2022-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"82481668","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Índices aterogénicos: utilidad como predictores en enfermedad cardiovascular 动脉粥样硬化指标:作为心血管疾病的预测指标
IF 1.6 Q3 Medicine Pub Date : 2022-09-01 DOI: 10.1016/j.arteri.2022.08.001
Juan José Tamarit García
{"title":"Índices aterogénicos: utilidad como predictores en enfermedad cardiovascular","authors":"Juan José Tamarit García","doi":"10.1016/j.arteri.2022.08.001","DOIUrl":"10.1016/j.arteri.2022.08.001","url":null,"abstract":"","PeriodicalId":45230,"journal":{"name":"Clinica e Investigacion en Arteriosclerosis","volume":null,"pages":null},"PeriodicalIF":1.6,"publicationDate":"2022-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"40351053","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Athrogenic indexes: Useful markers for predicting metabolic syndrome in axial spondyloarthritis 动脉粥样硬化指数:预测轴性脊柱炎代谢综合征的有用指标
IF 1.6 Q3 Medicine Pub Date : 2022-09-01 DOI: 10.1016/j.arteri.2022.03.005
Maroua Slouma , Khaoula Ben Ali , Lobna Kharrat , Chadia Zouaoui , Haroun Ouertani , Imen Gharsallah

Introduction

Metabolic syndrome is a pathological entity associated with a high risk of cardiovascular disease. Data regarding the frequency of this syndrome, lipid profile, and atherogenic index of plasma in patients with radiographic axial spondyloarthritis are scarce.

We aim to determine the prevalence of metabolic syndrome in patients with spondyloarthritis. We also aim to determine discriminative values of atherogenic indexes between patients with and without metabolic syndrome.

Methods

We conducted a cross-sectional study including 51 patients meeting the ASAS 2009 criteria for radiographic axial spondyloarthritis. We measured the following parameters: triglyceride (TG), high-density lipoproteins (HDLc), low-density lipoprotein cholesterol (LDLc), and total cholesterol (TC). We calculated TC/HDLc, TG/HDLc, LDLc/HDLc ratios, and atherogenic index of plasma (LogTG/HDLc).

Results

Metabolic syndrome was noted in 33% of cases. Patients with active disease had a higher body mass index (26.89 ± 5.88 versus 23.63 ± 4.47 kg/m2, p = 0.03), higher TG (1.41 ± 0.64 versus 0.89 ± 0.5 mmol/L, p = 0.05) and a lower HDLc level (1 ± 0.28 versus 1.31 ± 0.22 mmol/L, p = 0.01). However, the LogTG/HDLc and TG/HDLc were higher in patients under TNFα inhibitors. The ability of the TG/HDLc ratio and LogTG/HDLc to distinguish patients with or without metabolic syndrome were good at cut-offs of 1.33 and 0.22, respectively (specificity: 91.2% and sensitivity 70.6% for both ratios).

Conclusion

Our study showed that metabolic syndrome is frequent in patients with axial spondyloarthritis. Atherogenic indexes can be used for predicting metabolic syndrome in these patients.

代谢综合征是一种与心血管疾病高风险相关的病理实体。关于该综合征的发生频率、脂质谱和x线轴性脊柱炎患者血浆动脉粥样硬化指数的资料很少。我们的目的是确定代谢综合征在脊椎关节炎患者中的患病率。我们还旨在确定有代谢综合征和无代谢综合征患者的动脉粥样硬化指标的鉴别值。方法我们进行了一项横断面研究,包括51例符合ASAS 2009放射学标准的轴性脊柱炎患者。我们测量了以下参数:甘油三酯(TG)、高密度脂蛋白(HDLc)、低密度脂蛋白胆固醇(LDLc)和总胆固醇(TC)。我们计算了TC/HDLc、TG/HDLc、LDLc/HDLc比率和血浆的动脉粥样硬化指数(LogTG/HDLc)。结果33%的患者出现代谢综合征。活动期患者体质量指数较高(26.89±5.88比23.63±4.47 kg/m2, p = 0.03), TG较高(1.41±0.64比0.89±0.5 mmol/L, p = 0.05), HDLc水平较低(1±0.28比1.31±0.22 mmol/L, p = 0.01)。然而,TNFα抑制剂组患者的LogTG/HDLc和TG/HDLc较高。TG/HDLc比值和LogTG/HDLc区分有无代谢综合征的截断值分别为1.33和0.22(特异性为91.2%,敏感性为70.6%)。结论我们的研究表明,代谢综合征在轴型脊柱炎患者中是常见的。动脉粥样硬化指数可用于预测这些患者的代谢综合征。
{"title":"Athrogenic indexes: Useful markers for predicting metabolic syndrome in axial spondyloarthritis","authors":"Maroua Slouma ,&nbsp;Khaoula Ben Ali ,&nbsp;Lobna Kharrat ,&nbsp;Chadia Zouaoui ,&nbsp;Haroun Ouertani ,&nbsp;Imen Gharsallah","doi":"10.1016/j.arteri.2022.03.005","DOIUrl":"10.1016/j.arteri.2022.03.005","url":null,"abstract":"<div><h3>Introduction</h3><p>Metabolic syndrome is a pathological entity associated with a high risk of cardiovascular disease. Data regarding the frequency of this syndrome, lipid profile, and atherogenic index of plasma in patients with radiographic axial spondyloarthritis are scarce.</p><p>We aim to determine the prevalence of metabolic syndrome in patients with spondyloarthritis. We also aim to determine discriminative values of atherogenic indexes between patients with and without metabolic syndrome.</p></div><div><h3>Methods</h3><p><span>We conducted a cross-sectional study including 51 patients meeting the ASAS 2009 criteria for radiographic axial spondyloarthritis. We measured the following parameters: triglyceride (TG), high-density lipoproteins (HDL</span><sub>c</sub>), low-density lipoprotein cholesterol (LDL<sub>c</sub>), and total cholesterol (TC). We calculated TC/HDL<sub>c</sub>, TG/HDL<sub>c</sub>, LDL<sub>c</sub>/HDL<sub>c</sub> ratios, and atherogenic index of plasma (LogTG/HDL<sub>c</sub>).</p></div><div><h3>Results</h3><p>Metabolic syndrome was noted in 33% of cases. Patients with active disease had a higher body mass index (26.89<!--> <!-->±<!--> <!-->5.88 versus 23.63<!--> <!-->±<!--> <!-->4.47<!--> <!-->kg/m<sup>2</sup>, <em>p</em> <!-->=<!--> <span>0.03), higher TG (1.41</span> <!-->±<!--> <!-->0.64 versus 0.89<!--> <!-->±<!--> <!-->0.5<!--> <!-->mmol/L, <em>p</em> <!-->=<!--> <!-->0.05) and a lower HDL<sub>c</sub> level (1<!--> <!-->±<!--> <!-->0.28 versus 1.31<!--> <!-->±<!--> <!-->0.22<!--> <!-->mmol/L, <em>p</em> <!-->=<!--> <!-->0.01). However, the LogTG/HDL<sub>c</sub> and TG/HDL<sub>c</sub> were higher in patients under TNFα inhibitors. The ability of the TG/HDL<sub>c</sub> ratio and LogTG/HDL<sub>c</sub> to distinguish patients with or without metabolic syndrome were good at cut-offs of 1.33 and 0.22, respectively (specificity: 91.2% and sensitivity 70.6% for both ratios).</p></div><div><h3>Conclusion</h3><p>Our study showed that metabolic syndrome is frequent in patients with axial spondyloarthritis. Atherogenic indexes can be used for predicting metabolic syndrome in these patients.</p></div>","PeriodicalId":45230,"journal":{"name":"Clinica e Investigacion en Arteriosclerosis","volume":null,"pages":null},"PeriodicalIF":1.6,"publicationDate":"2022-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"75593536","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 4
期刊
Clinica e Investigacion en Arteriosclerosis
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1